Published in Am J Gastroenterol on February 01, 2001
The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry. Gastroenterology (2013) 1.51
Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol (2014) 1.25
Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol (2008) 1.17
Paraneoplastic neurological syndromes. Clin Exp Immunol (2014) 1.12
Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease. Gut (2003) 1.08
Paraneoplastic syndromes in ganglioneuroblastoma: contrasting symptoms of constipation and diarrhoea. Eur J Pediatr (2003) 0.93
Progress in the management of limited-stage small cell lung cancer. Cancer (2013) 0.93
Enteric autoantibodies and gut motility disorders. Gastroenterol Clin North Am (2008) 0.93
New perspectives in the diagnosis and management of enteric neuropathies. Nat Rev Gastroenterol Hepatol (2013) 0.92
Diagnostic and therapeutic approach to pancreatic cancer-associated gastroparesis: literature review and our experience. Dig Dis Sci (2008) 0.86
Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based case-control study. Dig Dis Sci (2010) 0.83
A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer (2011) 0.83
Autonomic involvement in subacute and chronic immune-mediated neuropathies. Autoimmune Dis (2013) 0.80
A Rare Case of Paraneoplastic Syndrome Presented with Severe Gastroparesis due to Ganglional Loss. Case Rep Med (2012) 0.80
The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res (2014) 0.76
Pseudoachalasia of the cardia secondary to nongastrointestinal neoplasia. Dysphagia (2007) 0.76
Paraneoplastic oesophageal dysmotility-renal cell carcinoma presenting as dysphagia: a case report. Cases J (2009) 0.75
Autoimmune Gastrointestinal Paralysis: Failure of Conventional Treatment without Immunomodulation. Case Rep Surg (2014) 0.75
Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility. Gastroenterol Hepatol (N Y) (2013) 0.75
Variation in annual volume at a university hospital does not predict mortality for pancreatic resections. HPB Surg (2009) 0.75
Anti-Hu antibodies activate enteric and sensory neurons. Sci Rep (2016) 0.75
Malignancy-associated gastroparesis: an important and overlooked cause of chronic nausea and vomiting. BMJ Case Rep (2014) 0.75
Achalasia secondary to lung adenocarcinoma. Korean J Intern Med (2015) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 4.93
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med (2000) 3.57
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology (1997) 2.71
Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil (2006) 2.61
The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med (1992) 2.54
Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci (1976) 2.48
Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut (1987) 2.46
Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med (1975) 2.43
Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther (2002) 2.37
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Assessment of gastric accommodation: overview and evaluation of current methods. Neurogastroenterol Motil (2004) 2.28
Immunoglobulins promote remyelination in the central nervous system. Ann Neurol (1990) 2.27
Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci (1989) 2.23
American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil (2008) 2.16
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med (1999) 2.12
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology (1998) 2.08
Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology (1986) 2.03
Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil (2007) 1.98
Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology (1991) 1.98
Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol (2000) 1.93
Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol (1990) 1.90
Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am J Gastroenterol (1998) 1.88
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.85
Is there a role for gastric accommodation and satiety in asymptomatic obese people? Obes Res (2001) 1.84
Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol (1985) 1.81
Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology (1997) 1.80
Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology (1986) 1.79
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology (1977) 1.78
Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology (2000) 1.74
Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil (2009) 1.73
Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil (2011) 1.72
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology (2001) 1.64
Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology (2011) 1.64
Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology (1991) 1.63
Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil (2004) 1.63
Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med (2000) 1.61
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil (2005) 1.60
Adrenergic modulation of human colonic motor and sensory function. Am J Physiol (1997) 1.59
[13C]octanoic acid breath test for gastric emptying of solids: accuracy, reproducibility, and comparison with scintigraphy. Gastroenterology (1997) 1.59
Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest (1984) 1.59
Scintigraphy of the whole gut: clinical evaluation of transit disorders. Mayo Clin Proc (1995) 1.58
Development of a test to measure gastric accommodation in humans. Am J Physiol (1999) 1.56
Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med (1997) 1.54
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med (1976) 1.53
Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut (2003) 1.53
Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology (1999) 1.52
Gastric mechanosensory and lower esophageal sphincter function in rumination syndrome. Am J Physiol (1998) 1.51
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med (1978) 1.51
Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids. Neurogastroenterol Motil (2009) 1.51
The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology (1995) 1.50
Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology (1986) 1.49
Effects of erythromycin on gut transit in pseudo-obstruction due to hereditary coproporphyria. J Clin Gastroenterol (1992) 1.48
Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology (1994) 1.47
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut (2008) 1.47
Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc (1992) 1.46
Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology (1995) 1.46
Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology (1998) 1.46
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 1.45
Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med (1993) 1.45
ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol (2001) 1.45
Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci (1976) 1.43
Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology (1999) 1.42
Gastrointestinal manifestations of systemic vasculitis. Q J Med (1983) 1.41
Seronegativity for type 1 antineuronal nuclear antibodies ('anti-Hu') in subacute sensory neuronopathy patients without cancer. Neurology (1993) 1.41
Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology (1992) 1.41
Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil (2004) 1.40
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil (2003) 1.39
Immunologic properties of the main encephalitogenic peptide from the basic protein of human myelin. J Immunol (1970) 1.39
Neurological autoimmunity targeting aquaporin-4. Neuroscience (2009) 1.39
New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol (2000) 1.38
Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature (1980) 1.38
Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut (1994) 1.37
The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies. Neurology (1994) 1.36
Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil (2009) 1.35
Transitory expression of Thy-1 antigen in skeletal muscle development. Nature (1977) 1.32
Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil (2009) 1.32
American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Gastroenterology (1999) 1.32
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro. Proc Natl Acad Sci U S A (1978) 1.31
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut (1999) 1.31
Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol (1995) 1.30
Descending perineum syndrome: audit of clinical and laboratory features and outcome of pelvic floor retraining. Am J Gastroenterol (1999) 1.30
The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci (1976) 1.30
Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol (2001) 1.29
Effect of age on the enteric nervous system of the human colon. Neurogastroenterol Motil (2009) 1.29